ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1428

Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Abstract Number: 0079

Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Abstract Number: 1933

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Abstract Number: 0440

Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Abstract Number: 1132

Association Between Serum Selenium Level and the Prevalence of Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Abstract Number: 0334

Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
Abstract Number: 0074

Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
Abstract Number: 0962

Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Abstract Number: 0611

Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists
Abstract Number: 1920

Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
Abstract Number: 0085

Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Abstract Number: 0082

Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Abstract Number: 0717

Association of Fatigue with Disease Activity in Myositis
Abstract Number: 0877

Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Abstract Number: 1121

Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].